Key Market Indicators
Israeli pharmaceutical research and development expenditure is projected to decline to approximately $134 million PPP by 2028, down from nearly $190 million PPP in 2023. This marks an average annual decrease of 5.6%. Since 2015, Israel has experienced a gradual reduction in its pharmaceutical R&D spending, with a year-on-year decline of 0.5%. In the 2023 rankings, Israel placed 12th, with Finland surpassing it with an expenditure of almost $190 million PPP. Globally, China, Germany, and South Korea secured the 2nd, 3rd, and 4th positions, respectively, in pharmaceutical R&D expenditure rankings.
